Repeat Chlamydia trachomatis testing among heterosexual STI outpatient clinic visitors in the Netherlands: a longitudinal study. by Visser, Maartje et al.
RESEARCH ARTICLE Open Access
Repeat Chlamydia trachomatis testing
among heterosexual STI outpatient clinic
visitors in the Netherlands: a longitudinal
study
Maartje Visser1* , Fleur van Aar1, Femke D. H. Koedijk2, Carolina J. G. Kampman2 and Janneke C. M. Heijne1
Abstract
Background: Chlamydia infections are common in both men and women, are often asymptomatic and can cause
serious complications. Repeat testing in high-risk groups is therefore indicated. In the Netherlands, guidelines on
repeat chlamydia testing differ between testing facilities, and knowledge on repeat testing behaviour is limited.
Here, we analyse the current repeat testing behaviour of heterosexual STI clinic visitors, and aim to identify groups
for which repeat testing advice could be advantageous.
Methods: Longitudinal surveillance data from all Dutch STI outpatient clinics were used, which included all STI
clinic consultations carried out among heterosexual men and women between June 2014 and December 2015.
Repeat testing was defined as returning to the same STI clinic between 35 days and 12 months after initial
consultation. We calculated chlamydia positivity at repeat test stratified by initial test result and time between
consultations. Logistic regression analyses were used to identify predictors of repeat testing, and predictors of
having a chlamydia positive repeat test.
Results: In total, 140,486 consultations in 75,487 women and 46,286 men were available for analyses. Overall, 15.4%
of women and 11.1% of men returned to the STI clinic within the study period. Highest chlamydia positivity at
repeat test was seen 3–5 months after initial positive test. Among both women and men, repeat testing was
associated with non-Western ethnicity, having had more than two sex partners in the past 6 months, reporting STI
symptoms, having a history of STI, and having a chlamydia positive initial test. Among repeat testers, chlamydia
positive repeat test was most strongly associated with younger age, followed by a chlamydia positive initial test.
Conclusions: Repeat testing most often resulted in a positive test result among young heterosexuals (<25) and
heterosexuals of any age with a chlamydia infection at the initial consultation. Further efforts are needed to
determine optimal repeat testing strategies.
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Background
Chlamydia trachomatis (chlamydia) is the most fre-
quently reported bacterial sexually transmitted infection
(STI) among heterosexuals [1]. Chlamydia reinfections
are also common, with proportions of reinfection of up
to 32% in women [2], and 18.3% in men [3]. Chlamydia
infections are associated with increased risk of complica-
tions such as pelvic inflammatory disease (PID) [4–6].
Repeat testing for chlamydia could identify chlamydia
infections at an early stage of infection, thereby possibly
reducing the individual risk of complications, and might
lead to reduced transmission at the population level [4–6].
Therefore, several countries have established STI care
guidelines on repeat testing for heterosexuals [7–10].
Repeat testing guidelines differ between countries with
regard to the groups that are targeted, and the advised
timing of the repeat test. A mathematical modelling
study estimated the risk of a repeat chlamydia infection
to be highest 2–5 months after treatment, suggesting a
possible window for repeat testing in case of an initial
positive test [11]. This is in line with the recommended
test interval in most countries for repeat testing after
chlamydia infection: the US centre for disease control
and prevention recommends men and women to return
preferably 3 months after treatment, and at least within
12 months [7]. In Australia, repeat testing at 3 months is
recommended [8], and European and UK guidelines
recommend repeat testing 3–6 months after treatment
for both men and women aged <25 years [9, 10]. Repeat
testing after a negative chlamydia test is not explicitly
recommended, but annual chlamydia screening is
advised in the European and US guidelines for all sexu-
ally active men and women aged <25, or women aged
<25, respectively [7, 9].
In the Netherlands, guidelines on repeat testing are
limited. For men who have sex with men, advice is given
to test for STI every 6 or 3 months, depending on risk
behaviour [12]. For heterosexuals, guidelines on repeat
testing are only established for initial chlamydia positive
persons, and differ between testing facilities. In general
practitioner guidelines, it is advised to retest patients
within 12 months after treatment of an initial infection
[13]. STI clinic guidelines recommend repeat testing 4–
6 months after treatment [12]. However, while the repeat
testing behaviour of MSM has been studied in the past
[14, 15], it is not well known to what extend the guidelines
for heterosexuals are currently being adhered to. In
addition, knowledge on repeat testing among heterosexual
STI clinic visitors with an initial negative chlamydia test is
limited. Besides initial chlamydia positive attendees, the
initial negative attendees are also of interest because
Dutch STI clinics are restricted to people at increased risk
of STI. Initial negative visitors could therefore still be a
potential target group for repeat testing.
Two Dutch studies assessed the uptake of repeat
testing after chlamydia infection at STI clinics, with
differing results. One study found that 33.4% of all
chlamydia positive individuals returned for a repeat test
3–12 months after treatment [16], whereas the other
study found 9.2% repeat testing at 5–8 months after
treatment among young heterosexuals [17]. However,
these studies used regional STI clinic data only, and did
not assess repeat testing behaviour and the chlamydia
prevalence at repeat consultation among visitors with an
initial chlamydia negative test result.
To inform further specification of the Dutch guide-
lines, and to be able to evaluate them properly in the
future, more insight is needed into current chlamydia re-
peat testing behaviour among Dutch heterosexual STI
clinic visitors. In this study, we aimed to describe
current repeat testing behaviour and to identify groups
for which repeat testing advice could be advantageous.
We do this by determining repeat testing uptake and by
identifying predictors of repeat testing and predictors of
chlamydia positivity at repeat test among heterosexual
STI clinic visitors with both an initial negative or an
initial positive chlamydia test.
Methods
Study design
This study used Dutch STI clinic surveillance data, con-
taining all consultations from all STI outpatient clinics
in the Netherlands. The STI clinic surveillance data con-
tains information on personal characteristics, sexual be-
haviour, and STI diagnoses of each patient at each
consultation. As STI testing at Dutch STI clinics is pub-
licly funded, it is restricted to certain target groups who
are considered at high risk for STI based on positivity
rates obtained from the STI clinic surveillance data (fur-
ther referred to as high risk populations) [18]. Hetero-
sexual men and women aged 24 years or younger and
MSM are considered at high risk for STI regardless
behavioural or other risk factors. Heterosexual men and
women aged 25 years and older are allowed to test at
the clinics if they report at least one of the following fac-
tors: having STI symptoms, being notified by an infected
partner, originating from or having a partner from a
non-Western area, being a commercial sex worker, hav-
ing had an STI in the past year, being a victim of sexual
violence, or for women having an MSM partner [18].
For this study, we used data from June 1st 2014 to
December 31st 2015, as in June 2014 a personal identifi-
cation number was added to data collection, which
enabled linkage of consultations performed on the same
individuals at the same STI clinic. We selected consulta-
tions of heterosexual men and women who had at least
one chlamydia test between June 2014 and December
2015. Individuals who reported having had sex with only
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the opposite gender in the past 6 months were defined
as heterosexuals in this study. Thereby this term does
not necessarily reflect the sexual identity of the individ-
ual, but rather their self-reported behaviour. Consulta-
tions where no chlamydia test was recorded, or that had
missing information on chlamydia diagnosis were
excluded. STI tests that were not performed at STI
clinics, but at other health care settings such as general
practitioners or hospitals could not be included, as sys-
tematically collected data are not available for these
facilities.
The main outcome of interest was repeat testing,
which was defined as returning to the STI clinic for a
second consultation within 12 months after the initial
visit. Individuals were defined as single testers if they
had only one STI clinic visit during the study period, or
if they returned to the STI clinic after more than
12 months from the initial visit. Although a test of cure
(TOC) is generally not recommended in the Netherlands,
consultations that were performed within 35 days after
the initial consultation were deleted to minimise the risk
that possible TOCs were included. Also, the 35 day cut off
limits the chance of a repeat test being positive due to re-
sidual bacterial material from an already treated chlamydia
infection at the initial consultation [19]. Persons with their
first consultation within 35 days of the end of the study
period (December 31st 2015) were excluded, as they had
no opportunity for a repeat test. All analyses were per-
formed using the first two consultations of each individ-
ual. Chlamydia positivity was defined as a diagnosed
chlamydia infection at any location (urogenital, anorectal,
or oral). Chlamydia diagnoses were based on nucleic acid
amplification test (NAAT).
Statistical analyses
All analyses were performed for men and women separ-
ately because of differences in chlamydia positivity rates
and STI clinic visiting behaviour between women and
men [18]. First, descriptive analyses were performed. We
calculated the time between consecutive consultations of
each individual, stratified by the initial test result. We
also calculated chlamydia positivity of repeat tests,
stratified by time between initial test and repeat test.
Second, we identified predictors of repeat testing using
logistic regression analysis, comparing single testers with
repeat testers. For this analysis, characteristics from the
initial consultation were used, because the initial
consultation is the moment when repeat testing advice
based on person characteristics can be given. Age was
included in three categories; 13–19, 20–24, and 25+, as
in the Netherlands persons aged <20 have highest chla-
mydia positivity rates at STI clinics, and for persons
aged >24 different triaging guidelines are in place [18].
Ethnicity was based on country of birth of both the
participant and its parents, according to the definitions
of Statistics Netherlands [20]. Persons from Western
Europe, Northern America, and Australia were consid-
ered of Western non-Dutch ethnicity. All other ethnici-
ties were grouped as non-Western, which is the same
categorisation as used in triage at the STI clinics. An
uncertainty analysis was performed to evaluate whether
categorisation of ethnicity into more subgroups would
provide different results. All other characteristics were
self-reported, except for the chlamydia diagnoses. Some
variables could not be included in the logistic regression
due to small group sizes, and were only included in
descriptive analyses (region of the STI clinic, being HIV
positive, being (client of ) commercial sex worker, and
being a swinger).
Variables were included in multivariable analysis when
significant in univariable analysis (P < 0.1). If a variable had
more than 5% missing values, missings were included in
the analysis as a separate category to reduce loss of data. A
complete case analysis was performed as uncertainty ana-
lysis to evaluate robustness of the model for missing data.
The multivariable model was made using backward elimin-
ation, using a significance level of 0.05. Because a chlamydia
infection at the initial consultation could influence the
identified predictors of repeat testing (these people are
more likely to receive repeat testing advice), effect modifica-
tion by chlamydia infection at initial consultation was
assessed by adding interaction terms and stratifying ana-
lyses. Furthermore, since only 1.5 years of data was avail-
able, some people might have had limited opportunity to
return for a repeat test within the timeframe of this study.
To identify the consequences of this, uncertainty analyses
were performed in which only persons with a minimum of
12 months of follow-up time were included.
Last, to assess predictors of having a chlamydia positive
repeat test within 1 year after initial consultation, logistic
regression analysis was done among the groups of repeat
testers. Again, characteristics from the initial consultation
and the same methods were used. However, missings were
in this model not included as a separate category, as the
number of individuals in these groups would become too
small for multivariable analysis. The same variables were
used as in the previous analysis, with the addition of time
between first and repeat test, categorised in ≤6 months
and >6 months. An uncertainty analysis was performed
using characteristics from the consultation of the repeat
test, instead of characteristics from the initial consultation.




Between June 2014 and December 2015, 152,358 consul-
tations were carried out at the STI clinics in the
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Netherlands among 127,650 heterosexual men and
women. We excluded 324 consultations because there
was missing chlamydia data or no chlamydia test was
registered, and 563 consultations because they took
place within 35 days of the previous consultation. Five
thousand six hundred sixty-five persons were excluded
because they did not have more than 35 days of follow-
up time. Last, 5320 consultations were excluded because
they were performed after the second consultation, leav-
ing 140,486 consultations in 75,487 women and 46,286
men available for analysis. Characteristics at initial
consultation stratified for women and men are shown in
Additional file 1: Table S1.
Timing and predictors of repeat testing
In total, 15.4% of women and 11.1% of men returned for
at least one test within 1 year after the initial consult-
ation (repeat testers), an overall repeat testing rate of
13.7% (Table 1). For STI clinic visitors with an initial
chlamydia positive test, 21.1% returned for a repeat test
and among visitors with an initial negative test, 12.5%
returned for a repeat test. In the uncertainty analysis
including only persons with a minimum of 12 months of
follow-up time, the overall repeat testing increased to
22.7% among women and 16.7% among men. The
median time between first test and repeat test was simi-
lar for women (171 days) and men (170 days). Both
women and men with a positive initial test returned to
the STI clinic for testing sooner compared to individuals
with a negative initial test (Additional file 2: Figure S1).
The strongest predictors of repeat testing for men and
women were having had more than four sex partners in
the past 6 months (adjusted odds ratio [aOR] 2.27 for
women and aOR 2.80 for men), and a chlamydia infection
at initial consultation (aOR 2.00 for women and aOR 1.85
for men) (Tables 2 and 3). Furthermore, for women, vari-
ables predictive for repeat testing were Non-Western eth-
nicity, use of a condom at last sexual contact, reporting
STI symptoms, and having had an STI in the past year. A
slightly lower odds of repeat testing was observed for hav-
ing a high education level, being of western non-Dutch
ethnicity, and having received partner notification. Among
men, results were comparable except for condom use and
partner notification at the initial consultation, which were
not associated with repeat testing. In addition, among
women, age was not a predictor of repeat testing, but men
aged 25 years and older were less likely to be repeat testers
compared to 13 to 19 year olds.
Chlamydia infection at initial consultation was an ef-
fect modifier for repeat testing among both women and
men. However, none of the directions of effect changed
when analyses were stratified (Additional file 3: Table
S2). Among both women and men, the effect of number
of sex partners and history of STI was slightly weaker
among initial chlamydia positives. Among men, the ef-
fect of age became stronger among initial chlamydia
positives. The uncertainty analysis including persons
with a minimum of 12 months of follow-up time,
showed that predictors of repeat testing in the logistic
regression analysis hardly changed. Only among women,
the analysis showed that older women (>25) were less
often repeat testers (Additional file 4: Table S3). Uncer-
tainty analyses using complete cases only showed very
little differences in the found predictors of repeat testing
(compared to the main analyses), indicating that the ana-
lyses were also robust to missing values (Additional file 5:
Table S4). Analyses including more subgroups for ethni-
city did not change the results, and did not reveal a spe-
cific non-Western ethnicity group as predictor of repeat
testing among women. Among men, Suriname, the
Dutch Antilles and Sub-Saharan Africa were associated
with more repeat testing in univariable analysis, but
numbers in the different subgroups were too low to per-
form multivariable analysis (Additional file 6: Table S5).
Repeat test positivity and predictors of positive repeat
tests
At repeat test, 13.4% of women and 16.7% of men
tested positive for chlamydia (compared to 14.1% and
15.1% at initial test). Both for women (Fig. 1a) and
men (Fig. 1b), chlamydia positivity at repeat test was
higher among individuals with a positive initial test
compared to individuals with an initial negative test.
Especially between 3 and 5 months after the initial
test a clear difference can be seen between people
with an initial positive and negative test, as positivity
Table 1 Testing characteristics of heterosexuals at Dutch STI
clinics between June 2014 and December 2015
Women Men
Total number of consultations 88,409 52,077
Individuals with N consultations (%)
1 62,565 (82.9) 40,495 (87.5)
2 12,922 (17.1) 5791 (12.5)
Total number of individuals 75,487 46,286
Individuals with a repeat test
within 12 months (overall) (%)
11,612 (15.4) 5157 (11.1)
Repeat testers among initial
CT negatives (%)
9136/64,842 (14.1) 3910/39,283 (10.0)
Repeat testers among initial
CT positives (%)
2476/10,645 (23.3) 1247/7003 (17.8)
Median time between initial
test and repeat test (overall),
days (IQR)
171 (111–243) 170 (106–245)
After initial negative test 178 (116–249) 176 (112–252)
After initial positive test 147 (90–218) 147 (90–221)
IQR interquartile range, CT Chlamydia
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rates of over 25% were found in repeat tests after an
initial positive test, while chlamydia positivity of re-
peat tests after an initial negative test remained con-
stant over time.
Among the repeat testers, being aged >25 years
greatly reduced the odds of a chlamydia positive re-
peat test among both women and men (aOR 0.44 and
aOR 0.50, respectively) (Table 4). Furthermore, among
women, a chlamydia infection at initial consultation
was associated with higher risk for repeat infection,
whereas condom use at last sexual contact showed a
protective effect. Among men, significant interaction
was found between reporting STI symptoms and
chlamydia diagnosis; hence, a combined variable was
made. For men, having both a chlamydia infection
and reporting STI symptoms at initial consultation
was associated with increased risk of repeat test
positivity (aOR 2.30). Table 5 shows a side by side
comparison of predictors of repeat testing and repeat
test positivity.
Table 2 Predictors of repeat testing among heterosexual women at initial consultation, June 2014 to December 2015
Single testers Repeat testers
Crude Adjusted
n % n % OR 95% CI OR 95% CI
Total 63,875 84.6 11,612 15.4
Age
13–19 8543 13.4 1559 13.4 1 – – –
20–24 36,471 57.1 6623 57.0 0.99 (0.94–1.05) – –
25+ 18,861 29.5 3430 29.5 1.00 (0.93–1.06) – –
Education levela
Low/medium 17,554 27.5 3201 27.6 1 – 1 –
High 37,118 58.1 5422 46.7 0.80 (0.76–0.84) 0.88 (0.84–0.93)
Ethnicity
Dutch 47,441 74.4 7906 68.2 1 – 1 –
Western non-Dutch 3718 5.8 613 5.3 0.99 (0.91–1.08) 0.91 (0.83–1.00)
Non-Western 12,650 19.8 3081 26.6 1.46 (1.40–1.53) 1.31 (1.26–1.39)
Number of sex partners in past 6 months
0–1 21,107 33.7 2461 22.3 1 – 1 –
2–3 29,046 46.4 5162 46.7 1.52 (1.45–1.60) 1.56 (1.48–1.64)
4+ 12,471 19.9 3421 31.0 2.35 (2.22–2.49) 2.27 (2.14–2.41)
Condom use at last sexual contact
No 48,663 78.5 8214 72.6 1 – 1 –
Yes 13,294 21.5 3097 27.4 1.38 (1.32–1.44) 1.10 (1.04–1.15)
Received partner notification
No 53,816 84.7 9953 86.1 1 – 1 –
Yes 9749 15.3 1610 13.9 0.89 (0.84–0.95) 0.80 (0.75–0.85)
Reported STI symptoms
No 41,179 64.9 7253 62.8 1 – 1 –
Yes 22,257 35.1 4287 37.2 1.09 (1.05–1.14) 1.08 (1.03–1.12)
History of STI (CT/GO/SY)a,b
No 52,597 82.4 9215 79.4 1 – 1 –
Yes 5072 7.9 1672 14.4 1.88 (1.77–2.00) 1.86 (1.74–1.98)
Chlamydia infection
No 55,706 87.2 9136 78.7 1 – 1 –
Yes 8169 12.8 2476 21.3 1.85 (1.76–1.94) 2.00 (1.89–2.11)
Abbreviations: CT chlamydia, GO gonorrhoea, SY syphilis
aMissing values included in the analysis as a separate category (ORs not shown)
bIn 2014, history of STI was asked regarding the past 2 years. In 2015 this changed to the past year only
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The uncertainty analyses using characteristics from the
consultation of the repeat test instead of the initial con-
sultation showed similar results, but receiving partner
notification and reporting symptoms also remained in
the model, and became the strongest determinants for a
positive repeat test (Additional file 7: Table S6). Uncer-
tainty analyses for predictors of having a positive repeat
test with persons with a minimum of 12 months follow-
up time were not possible due to small sample size.
Discussion
Overall, 15% of heterosexual women and 11% of hetero-
sexual men visiting Dutch STI clinics between June 2014
and December 2015 returned to the same clinic for
repeat testing within the study period. The strongest
predictors of repeat testing were having had more than
four sex partners in the past 6 months and having a
chlamydia infection at the initial consultation. Reinfec-
tion rates were highest among initial chlamydia positives
Table 3 Predictors of repeat testing among heterosexual men at initial consultation, June 2014 to December 2015
Single testers Repeat testers
Crude Adjusted
n % n % OR 95% CI OR 95% CI
Total 41,129 88.9 5157 11.1
Age
13–19 2596 6.3 299 5.8 1 – 1 –
20–24 19,139 46.5 2582 50.1 1.17 (1.03–1.33) 1.08 (0.94–1.23)
25+ 19,394 47.2 2276 44.1 1.02 (0.90–1.16) 0.82 (0.72–0.93)
Education levela,c
Low 12,971 31.5 1516 29.4 1 – 1 –
High 22,363 54.4 2376 46.1 0.91 (0.85–0.97) 0.98 (0.91–1.06)
Ethnicity
Dutch 26,964 65.6 3006 58.3 1 – 1 –
Western non-Dutch 2524 6.1 322 6.3 1.14 (1.01–1.29) 1.06 (0.93–1.20)
Non-Western 11,602 28.2 1828 35.4 1.41 (1.33–1.50) 1.37 (1.28–1.46)
Number of sex partners in past 6 months
0–1 8559 21.0 529 10.4 1 – 1 –
2–3 16,191 39.7 1783 34.9 1.78 (1.61–1.97) 1.75 (1.58–1.94)
4+ 16,023 39.3 2801 54.8 2.83 (2.57–3.12) 2.80 (2.54–3.09)
Condom use at last sexual contact
No 29,257 73.8 3720 74.5 1 – – –
Yes 10,376 26.2 1273 25.5 0.96 (0.90–1.03) – –
Received partner notification
No 30,763 75.2 3917 76.2 1 – – –
Yes 10,155 24.8 1223 23.8 0.95 (0.88–1.01) – –
Reported STI symptoms
No 26,968 65.9 3135 61.1 1 – 1 –
Yes 13,939 34.1 1995 38.9 1.23 (1.16–1.31) 1.10 (1.03–1.17)
History of STI (CT/GO/SY)a,b
No 34,088 82.9 4103 79.6 1 – 1 –
Yes 2610 6.4 721 14.0 2.30 (2.10–2.51) 2.08 (1.90–2.28)
Chlamydia infection
No 35,373 86.0 3910 75.8 1 – 1 –
Yes 5756 14.0 1247 24.2 1.96 (1.83–2.10) 1.85 (1.72–1.99)
Abbreviations: CT chlamydia, GO gonorrhoea, SY syphilis
aMissing values included in the analysis as a separate category (ORs not shown)
bIn 2014, history of STI was asked regarding the past 2 years. In 2015 this changed to the past year only
cIncluded in the multivariable model due to significance of the ‘missing values’ category (not shown)
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at three to 5 months after the initial consultation, with
positivity rates over 25%. Chlamydia infection at the ini-
tial consultation and young age were strong predictors
for having a chlamydia positive repeat test.
This study uses national STI clinic surveillance data,
which results in a very large study population, allowing
extensive analyses among both initial negative and initial
positive visitors. However, there are also limitations to
this study. First, linkage of consultations by ID number
was only possible for individuals returning to the same
STI clinic. Hence, (repeat) tests at other STI clinics or
other testing facilities, such as general practitioners or
online STI test providers, are not included and this
might have resulted in an underestimation of the repeat
testing rates. From 2016 onwards, STI clinics ask their
attendees if and where they tested for STI in the past
year. These new data might provide future insight in re-
peat testing between STI clinics and from other testing
facilities to the STI clinics. Second, as this study used
STI clinic surveillance data, only information on individ-
uals who actively returned to the STI clinic was avail-
able. The positivity rates in people not returning to the
clinics are unknown, which hampers generalisability of
our results to all STI clinic visitors. Third, longitudinal
data has only been available since June 2014, which
resulted in a relative short follow-up time of 1.5 years.
Consequently, we have underestimated the percentage of
repeat testers as single testers might have returned for a
repeat test after the follow-up period, and single testers
might have been misclassified if the initial consultation
in our data was actually already a repeat test. Uncer-
tainty analyses showed that including only people with a
minimum of 12 months follow-up did increase the per-
centage of repeat testers, but hardly changed the found
determinants of repeat testing, indicating that our re-
sults were robust for follow-up time. Last, we only
included the first two consultations of each individual.
As only a small percentage of people had more than two
consultations, we expect this exclusion not to have influ-
enced our results.
We found that overall, 13.7% of heterosexuals visiting
STI clinics returned for a repeat chlamydia test during
our study period, and 20.5% when including only people
with a minimum of 1 year follow-up. This is slightly
lower than a study among UK genitourinary medicine
clinic visitors, where a repeat chlamydia testing inci-
dence of 26 per 100 person years was found [21]. Our
study showed that 21.1% returned after an initial positive
A
B
Fig. 1 Chlamydia positivity at repeat test by month after initial test, split by initial test result in heterosexual women (a) and men (b) testing at
STI outpatient clinics in the Netherlands between June 2014 and December 2015. Months were defined as 30 days, and tests performed within
35 days after the initial consultation were not included
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test, which was also lower than a study using US labora-
tory data, where repeat testing was 38% in women and
22% in men after an initial positive test [22]. Our esti-
mate is, however, in the middle of two other regional
estimates from the Netherlands (9.2% [17] and 33.4%
[16] of repeat tests after an initial positive test). Differ-
ences between our study findings and others can be
explained by differences in study population, definition
of repeat test, and duration of follow-up. Among
women, the percentage of repeat testers was higher than
among men. This is in line with other Dutch studies on
repeat testing [16, 17, 23]. This could be due to the fact
that women are known to generally seek health-related
information and health care more often than men [24, 25].
Last, we showed that repeat test positivity rates were high-
est among initial chlamydia positives between 3 and
5 months after the initial consultation, which is in line with
findings from other studies [11, 26] and current repeat test-
ing guidelines after CT infection elsewhere [7–10].
Predictors of repeat testing found in our study were
mostly characteristics associated with- or indicative of
sexual risk behaviour and risk of STI: higher number of
partners, non-Western ethnicity [18, 27], history of STI
infection, and chlamydia infection at initial consultation.
This might indicate that individuals who are at increased
risk are also more motivated to test repeatedly. However,
it could also be a consequence of the STI clinic policies,
since non-Western ethnicity is a triaging criterion and
therefore facilitates admittance to the STI clinic. Strik-
ingly, we did not find young age (<25) to be predictive
of repeat testing among women in our main analysis,
and only a small effect among men, despite the fact that
being aged <25 also is an important triaging criterion. In
the uncertainty analyses with persons with a minimum
of 12 months follow-up time, women aged >25 were less
often repeat testers, which was more in line with the
triaging criteria. However, sample sizes were much
smaller in the uncertainty analysis, making these results
Table 4 Predictors of having a chlamydia positive repeat test among repeat testers, using initial STI clinic consultation characteristicsa
Crude Adjusted
OR 95% CI OR 95% CI
Women
Age
13–19 1 – 1 –
20–24 0.77 (0.66–0.88) 0.82 (0.70–0.95)
25+ 0.38 (0.32–0.45) 0.44 (0.37–0.53)
Condom use at last sexual contact
No 1 – 1 –
Yes 0.69 (0.60–0.78) 0.83 (0.72–0.95)
Chlamydia infection at initial consultation
No 1 – 1 –
Yes 2.04 (1.81–2.29) 1.83 (1.62–2.06)
Men
Age
13–19 1 – 1 –
20–24 0.77 (0.58–1.02) 0.82 (0.61–1.09)
25+ 0.47 (0.35–0.63) 0.50 (0.37–0.66)
Combined variable, reported symptoms and chlamydia infection
CT negative, no STI symptoms 1 – 1 –
CT negative, reported STI symptoms 1.06 (0.88–1.27) 1.12 (0.93–1.34)
CT positive, no STI symptoms 1.07 (0.84–1.37) 1.00 (0.79–1.28)
CT positive, reported STI symptoms 2.31 (1.89–2.83) 2.30 (1.88–2.82)
aTable only includes variables that remained significant in multivariate analysis
Table 5 Comparison of predictors of repeat testing and predictors





Chlamydia infection Yes Yes
Young age No Yes
Non-Western ethnicity Yes No
More sex partners Yes No
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less reliable. Future research using longer time periods is
warranted to determine these associations with more
certainty.
The strongest predictor for a chlamydia positive
repeat test, among repeat testers, was young age. This
is in agreement with studies showing that young per-
sons are at increased risk of chlamydia infection [18,
28, 29]. Initial chlamydia infection (women) and
initial chlamydia infection combined with symptoms
(men) were also strong predictors for having a posi-
tive repeat test. Chlamydia infection being a predictor
for repeat infection is in line with findings from
studies from the UK, US, and Sweden [21, 22, 30].
Our analysis was corrected for several risk behaviour
parameters at initial consultation, such as number of
partners, but the association between initial and
repeat infection might be due to other behavioural or
biological factors as well. For example, repeat infec-
tions could be a consequence of inadequate partner
notification and/or treatment of the partner of the
infected index case thereby increasing the probability
of reinfection of the index case [31, 32]. Furthermore,
treatment failure could also contribute to the associ-
ation between initial and repeat positive test. In the
Netherlands, people tested positive at the urogenital
site receive 1 g of azithromycin, whereas those tested
positive at the anorectal site receive 7-days (100 mg
twice daily) doxycycline [33]. However, treatment
failure after urogenital or anorectal infections for
chlamydia is possible [34, 35]. For heterosexual men,
chlamydia infection was only associated with repeat
test positivity if symptoms were also reported. This
might indicate that for women and men different
mechanisms behind repeat infections are involved. A
possible explanation might be that women can be
reinfected from the anorectal site to the urogenital
site through autoinoculation [36]. At the STI clinics,
women are only tested for anorectal infection on
indication, which is likely to miss anal infections in
women who did not report recent anal intercourse
[37]. When women are infected at both anatomic
locations, but not tested at the anorectal site, they
receive azithromycin, which showed reduced effective-
ness for treating anorectal chlamydia infections [35].
This may cause higher rates of repeat infections due
to autoinoculation in women, whereas for heterosex-
ual men, autoinoculation is less likely [38].
When comparing the most important predictors of
repeat testing with predictors of having a chlamydia
positive repeat test among repeat testers, several import-
ant findings emerge. First, initial chlamydia infection
was associated with both repeat testing and with repeat
test positivity. This is an indication that initial positives
are indeed at increased risk of repeat infection. It also
shows that chlamydia positives are already returning
to the STI clinic more often compared to initial chla-
mydia negatives, following guidelines. However, still
only 21% of initial positives were repeat tester.
Second, young age (<25) was not associated with re-
peat testing in the main analysis, and was a strong
predictor of a chlamydia infection at repeat test. This
indicates that young people may not be returning to
the STI clinic more often, even though they are at
the highest risk of infection at repeat test compared
to the other ages. Therefore, young heterosexual STI
clinic visitors could be an important target group for
enhancing repeat testing. Third, non-Western ethni-
city was associated with repeat testing. However, at
repeat test, no difference in chlamydia positivity was
seen between persons with non-Western ethnicity
compared to persons with Dutch ethnicity. This find-
ing was unexpected, as more STIs are generally found
among those with non-Western ethnicity [18, 27].
This might indicate that the selection of persons with
non-Western ethnicity that do return to the STI
clinics for a repeat test, are not necessarily the ones
that are at highest risk of obtaining STIs. Or, vice
versa, that those with a Dutch ethnicity returning for
a repeated test are the ones with increased risk of
STI. The same thing was seen for number of part-
ners; having more partners was associated with repeat
testing, but not with positivity at the repeated test.
This could also indicate that those returning are not
necessarily the ones at highest risk.
Conclusions
Altogether, the results of this study provide an extensive
overview of current STI repeat testing behaviour among
Dutch heterosexual STI clinic attendees, which can be
used as guidance to determine for which groups repeat
testing could be most advantageous. Our findings suggest
that repeat testing could especially be beneficial for young
persons (<25 years) with an initial chlamydia infection.
However, interpretation of the results remains challenging
due to the use of surveillance data, and since the motiva-
tions of people to return (or not return) to the clinic
remain unknown. Furthermore, there is little insight into
the current practices of STI clinics regarding whether
(because of long waiting lists and high workload) and to
whom repeat testing advice is given. Gaining insight into
current practices is important to identify barriers and
attitudes toward repeat testing among health care
professionals, which should be taken into account when
evaluating the guidelines. More research is needed to
determine repeat testing strategies in the Netherlands
in terms of (cost) effectiveness, feasibility, and public
health impact.
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